Skip to main content

Peninsula biotech stock loses 80% after eye drug's late-stage study fails

The company still has a quartet of late-stage trials with the drug in various eye diseases and more than $700 million in cash.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.